Latest Breaking News On - Panbela therapeutics stock quote - Page 1 : comparemela.com

Following some good news for the company, Roth MKM analyst Jonathan Aschoff has maintained his “Buy” rating on Panbela Therapeutics.

Jenniferk simpsonJonathan aschoffPanbela therapeuticsPanbela therapeutics stock quoteFinancials nasdaqData safety monitoring board